Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2021 financial results on Wednesday, August 11, 2021.

Altimmune management will host a conference call for investors beginning at 8:30 am E.T. to discuss the second quarter 2021 financial results and provide a business update.

Conference Call Information:

Date: Wednesday, August 11
Time:  8:30 am Eastern Time
Domestic Dial-in:  (844) 615-6509
International Dial-in: (918) 922-3148
Conference ID:  9484516
Webcast: https://edge.media-server.com/mmc/p/ne5cqqtf

About AltimmuneAltimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (ALT-801), and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter

Investor and Media Contact:Will BrownChief Financial OfficerPhone: 240-654-1450wbrown@altimmune.com

Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Altimmune Charts.
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Altimmune Charts.